thalidomide has been researched along with Hepatitis E in 1 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Hepatitis E: Acute INFLAMMATION of the LIVER in humans; caused by HEPATITIS E VIRUS, a non-enveloped single-stranded RNA virus. Similar to HEPATITIS A, its incubation period is 15-60 days and is enterically transmitted, usually by fecal-oral transmission.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lenalidomide has a central role in the treatment of multiple myeloma and results in improved survival." | 7.85 | Hepatitis E during lenalidomide treatment for multiple myeloma in complete remission. ( Faber, LM; Kootte, RS, 2017) |
| "Lenalidomide has a central role in the treatment of multiple myeloma and results in improved survival." | 3.85 | Hepatitis E during lenalidomide treatment for multiple myeloma in complete remission. ( Faber, LM; Kootte, RS, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kootte, RS | 1 |
| Faber, LM | 1 |
1 other study available for thalidomide and Hepatitis E
| Article | Year |
|---|---|
Hepatitis E during lenalidomide treatment for multiple myeloma in complete remission.
Topics: Aged; Female; Hepatitis E; Humans; Immunologic Factors; Lenalidomide; Liver Function Tests; Maintena | 2017 |